Kyle Doherty

Kyle Doherty joined MJH Life Sciences in 2021 and is the lead editor for Oncology Fellows. He also produces print content for OncologyLive, as well as news and conference updates for OncLive.com. Email: kdoherty@mjhlifesciences.com

Articles

Ipilimumab Plus Nivolumab Increases 12-Month OS Rate vs SOC in nccRCC

September 17th 2024

Ipilimumab given in combination with nivolumab met the primary end point of 12-month OS rate vs SOC in patients with nccRCC in the SUNNIFORECAST trial.

Benmelstobart Plus Anlotinib Demonstrates Efficacy in Frontline Advanced RCC

September 17th 2024

Benmelstobart plus anlotinib improved PFS, OS, and ORR vs sunitinib in first-line advanced renal cell carcinoma.

Perioperative Nivolumab Shows EFS Benefit vs Placebo in Resectable NSCLC

September 15th 2024

Perioperative nivolumab extended event-free survival vs placebo in patients with resectable non–small cell lung cancer.

Early Switch Therapy to Atezolizumab After Vemurafenib/Cobimetinib Run-in Improves OS in BRAF V600–Positive Melanoma

September 15th 2024

Early switch therapy to atezolizumab after run-in with vemurafenib plus cobimetinib led to improved 4- and 5-month OS rates in BRAF V600–positive melanoma.

Retifanlimab Plus Carboplatin and Paclitaxel Offers PFS Benefit in Recurrent/Metastatic SCAC

September 14th 2024

The addition of retifanlimab to carboplatin and paclitaxel prolonged PFS for patients with chemotherapy-naive recurrent or metastatic SCAC.

Addition of Radium-223 to Enzalutamide Significantly Improves rPFS and OS in mCRPC

September 14th 2024

Radium-223 plus enzalutamide yielded significant rPFS and OS benefits vs enzalutamide monotherapy in metastatic castration-resistant prostate cancer.

Ibrilatazar Plus Chemotherapy Elicits Promising Activity in Recurrent Endometrial Cancer

September 12th 2024

Ibrilatazar plus paclitaxel/carboplatin led to a 100% disease-control rate in patients with advanced/recurrent endometrial cancer and was well tolerated.

Dr Hiltermann on ARTEMIDE-01 Data With Rilvegostomig in Metastatic NSCLC

September 11th 2024

T. Jeroen N. Hiltermann, MD, discusses findings from phase 1/2 ARTEMIDE-01 trial.

Dr Besse on Results From the CARMEN-LC03 Trial in Nonsquamous NSCLC

September 11th 2024

Benjamin Besse, MD, PhD, discusses findings from the phase 3 CARMEN-LC03 trial.

Timing of Immunotherapy Administration Is a Key Question to be Answered in Lung Cancer

September 11th 2024

Luis Raez, MD, highlights considerations with phases of treatment in lung cancer, detailing factors affecting use of adjuvant therapy when a patient has a complete response.

Dr Heymach on Updated AEGEAN Data in Resectable NSCLC

September 9th 2024

John V. Heymach, MD, PhD, discusses updated outcomes from the AEGEAN trial of perioperative durvalumab vs placebo in resectable non–small cell lung cancer.

Oral Rinse-Based Test Demonstrates Ability to Detect Recurrence of Head and Neck Cancer

September 9th 2024

A CD44 and total protein level detecting oral rinse-based test showed promise in identifying disease recurrence for patients with head and neck cancer.

The Treatment of Rare Tenosynovial Giant Cell Tumors Is Poised to Shift

September 5th 2024

R. Lor Randall, MD, FACS, details how he treats patients with TGCTs and the potential of vimseltinib to join pexidartinib in the treatment landscape.

ASCO Palliative Care Expert Panel Provides Recommendations to Integrate Health Equity Into Guideline Development

September 4th 2024

The ASCO Palliative Care Expert Panel has offered recommendations to add health equity measures to their palliative care and other future guidelines.

Luspatercept Is Under Evaluation in Non-Transfusion Dependent Lower-Risk Myelodysplastic Syndrome

September 3rd 2024

The phase 3 ELEMENT-MDS trial aims to expand access to luspatercept for anemia in non-transfusion dependent lower-risk MDS.

sNDA Withdrawn for Fruquitinib Plus Paclitaxel in Second-Line Gastric Cancer in China

August 30th 2024

The supplemental new drug application for fruquintinib plus paclitaxel in second-line gastric cancer in China has been voluntarily withdrawn.

NuTide:323 Study of NUC-3373 Regimen in Second-Line CRC is Discontinued

August 30th 2024

The NuTide:323 trial of NUC-3373 plus leucovorin, irinotecan, and bevacizumab in second-line colorectal cancer has been discontinued.

FDA Grants Orphan Drug Designation to NXP800 for ARID1a-Deficient Ovarian Cancers

August 29th 2024

NXP800 was granted orphan drug designation by the FDA for the treatment of ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers.

Merck to Discontinue KEYNOTE-867 and KEYNOTE-630 Trials of Pembrolizumab in NSCLC, CSCC

August 29th 2024

The phase 3 KEYNOTE-867 and KEYNOTE-630 trials evaluating pembrolizumab in NSCLC and CSCC, respectively, have been discontinued by Merck.

Nailing it Down: What Will AI’s Role Be in Cancer Care?

August 28th 2024

Krishnansu S. Tewari, MD, details the current and possible future applications of AI in cancer care as well as the limitations of the technology.